Why the Recce (ASX:RCE) share price is surging 8% higher today

The Recce Pharmaceuticals Ltd (ASX:RCE) share price is surging higher on Thursday following a promising update…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Recce Pharmaceuticals Ltd (ASX: RCE) share price has been a strong performer on Thursday.

In afternoon trade, the biotechnology company's shares are up 8.5% to $1.13.

jump in asx share price represented by man jumping in the air in celebration

Image source: Getty Images

Why is the Recce share price surging higher?

Investors have been bidding the Recce share price higher today following the release of a promising update.

According to the release, the company has announced positive results from a pre-clinical study investigating the Mechanism of Action (MoA) of its lead compound RECCE 327 (R327).

The company notes that R327 is a broad-spectrum synthetic anti-infective that has the potential to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.

Recce advised that the study was performed by independent, world leaders in bacterial MOA analysis and antibiotic profiling.

What were the results?

The release explains that R327's MoA was "unlike that of any antibiotic seen before" with multiple mechanisms identified in the study. These will be presented at an upcoming World Microbe Forum in June.

In addition, the study showed that R327 was rapidly and irreversibly bactericidal against Gram-negative Escherichia coli (E. coli) bacteria, in both active and stationary phase cells. Positively, it outperformed the best in class commercial antibiotics.

Management notes that current antibiotics rarely retain bactericidal activities against non-dividing bacterial cells. However, R327 shows significant activity against both slow-growing bacteria and actively dividing cells, thereby enabling continuous treatment of infections throughout the bacterial cell life cycle.

Recce's Executive Director & Chief Scientific Officer, Michele Dilizia, commented: "The data from this study further supports the potential of RECCE 327 to provide a novel and universal way to treat harmful infections. We are excited about these highly encouraging results as they provide important insights regarding how RECCE 327 is able to work repeatedly against the same strain of bacteria and their superbug forms."

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

a woman wearing a sparkly strapless dress leans on a neat stack of six gold bars as she smiles and looks to the side as though she is very happy and protective of her stash. She also has gold fingernails and gold glitter pieces affixed to her cheeks.
Share Gainers

If I'd invested $10,000 in this ASX 200 gold stock 3 years ago I'd have $101,538 today!

Investors have sent this ASX gold stock surging 915% in just three years. Let's see why.

Read more »

Two men celebrate while another holds his head in his hands, after watching the race.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant end to the trading week today.

Read more »

Two happy and excited friends in euphoria holding a smartphone, after winning in a bet.
Share Gainers

Why Appen, Guzman Y Gomez, Monadelphous, and PMET shares are racing higher today

These shares are ending the week on a positive note. But why?

Read more »

Five young people sit in a row having fun and interacting with their mobile phones.
Share Gainers

4 ASX 200 stocks rocketing higher this week

Investors sent these four ASX 200 shares flying higher this week. But why?

Read more »

A panel of four judges hold up cards all showing the perfect score of ten out of ten
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were back to the races this Thursday.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brightstar, Catapult Sports, IperionX, and Zip shares are charging higher

These shares are having a strong session on Thursday. What's going on?

Read more »

A woman's hand draws a stylised 'Top Ten' on a projected surface.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rather woeful Wednesday for investors.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Share Gainers

Why Catapult, GenusPlus, Meeka Metals, and TechnologyOne shares are pushing higher today

These shares are avoiding the market weakness on hump day. But why?

Read more »